Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy.

Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, Carducci MA, Denmeade SR, Markowski MC, Isaacs WB, Antonarakis ES, Pritchard CC, Eisenberger MA, Lotan TL.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00081. Epub 2019 Jul 26.

2.

A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer.

Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, Giunchi F, Platz EA, De Marzo AM, Mucci LA, Fiorentino M, Ebot EM.

Cancer Epidemiol Biomarkers Prev. 2019 Sep 18. doi: 10.1158/1055-9965.EPI-19-0713. [Epub ahead of print]

PMID:
31533941
3.

mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT/TFE regulation.

Asrani K, Murali S, Lam B, Na CH, Phatak P, Sood A, Kaur H, Khan Z, Noë M, Anchoori RK, Talbot CC Jr, Smith B, Skaro M, Lotan TL.

J Clin Invest. 2019 Nov 11. pii: 128287. doi: 10.1172/JCI128287. [Epub ahead of print]

4.

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM.

Clin Cancer Res. 2019 Sep 12. doi: 10.1158/1078-0432.CCR-19-1587. [Epub ahead of print]

PMID:
31515456
5.

The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy.

Faisal FA, Lotan TL.

Adv Anat Pathol. 2019 Sep 9. doi: 10.1097/PAP.0000000000000245. [Epub ahead of print]

PMID:
31503032
6.

PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy.

Haney NM, Faisal FA, Lu J, Guedes LB, Reuter VE, Scher HI, Eastham JA, Marchionni L, Joshu C, Gopalan A, Lotan TL.

J Urol. 2019 Sep 10:101097JU0000000000000533. doi: 10.1097/JU.0000000000000533. [Epub ahead of print]

PMID:
31502941
7.

Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.

Shenderov E, Isaacsson Velho P, Awan AH, Wang H, Mirkheshti N, Lotan TL, Carducci MA, Pardoll DM, Eisenberger MA, Antonarakis ES.

Prostate. 2019 Sep;79(13):1572-1579. doi: 10.1002/pros.23881. Epub 2019 Aug 7.

PMID:
31389628
8.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Sokol ES, Pavlick D, Frampton GM, Ross JS, Miller VA, Ali SM, Lotan TL, Pardoll DM, Chung JH, Antonarakis ES.

Oncologist. 2019 Jul 10. pii: theoncologist.2019-0214. doi: 10.1634/theoncologist.2019-0214. [Epub ahead of print]

PMID:
31292271
9.

Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease.

Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, Lotan TL, Hooper JE, Isaacs WB, Pienta KJ, De Marzo AM.

Eur Urol Oncol. 2019 Jul;2(4):429-436. doi: 10.1016/j.euo.2018.09.014. Epub 2018 Oct 19.

PMID:
31277779
10.

Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.

Alshalalfa M, Nguyen PL, Beltran H, Chen WS, Davicioni E, Zhao SG, Rebbeck TR, Schaeffer EM, Lotan TL, Feng FY, Mahal BA.

Eur Urol Oncol. 2019 Jul;2(4):405-412. doi: 10.1016/j.euo.2019.05.001. Epub 2019 Jun 2.

PMID:
31164324
11.

Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.

Alshalalfa M, Liu Y, Wyatt AW, Gibb EA, Tsai HK, Erho N, Lehrer J, Takhar M, Ramnarine VR, Collins CC, Den RB, Schaeffer EM, Davicioni E, Lotan TL, Bismar TA.

Int J Cancer. 2019 Dec 15;145(12):3453-3461. doi: 10.1002/ijc.32430. Epub 2019 Jun 10.

PMID:
31125117
12.

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.

Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00327. Epub 2019 Apr 18.

13.

Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.

Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL.

J Pathol. 2019 Sep;249(1):79-89. doi: 10.1002/path.5283. Epub 2019 May 24.

PMID:
30993692
14.

TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Kaur HB, Lu J, Guedes LB, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tomlins SA, Sfanos KS, Eisenberger M, Schaeffer EM, Joshu CE, Lotan TL.

Hum Pathol. 2019 May;87:95-102. doi: 10.1016/j.humpath.2019.02.006. Epub 2019 Mar 6.

PMID:
30851334
15.

SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.

Faisal FA, Kaur HB, Tosoian JJ, Tomlins SA, Schaeffer EM, Lotan TL.

Prostate Cancer Prostatic Dis. 2019 Mar 8. doi: 10.1038/s41391-019-0139-0. [Epub ahead of print]

PMID:
30850708
16.

If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.

Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL, Zheng Q, Bieberich CJ, Haffner MC, De Marzo AM.

Asian J Urol. 2019 Jan;6(1):10-25. doi: 10.1016/j.ajur.2018.11.006. Epub 2018 Dec 12. Review.

17.

DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.

Lotan TL, Kaur HB, Alharbi AM, Pritchard CC, Epstein JI.

Histopathology. 2019 May;74(6):836-843. doi: 10.1111/his.13806. Epub 2019 Apr 1.

PMID:
30636012
18.

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, Davis JW, Mohler JL, Trock BJ, Klein EA, Tosoian JJ, Hyndman ME, Bismar TA.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):399-405. doi: 10.1038/s41391-018-0101-6. Epub 2018 Dec 12.

19.

Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.

Faisal FA, Tosoian JJ, Han M, Macura KJ, Pavlovich CP, Lotan TL.

J Urol. 2019 May;201(5):937-942. doi: 10.1016/j.juro.2018.10.023.

PMID:
30414957
20.

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.

Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, Lotan TL.

Eur Urol. 2019 Mar;75(3):378-382. doi: 10.1016/j.eururo.2018.10.009. Epub 2018 Oct 15.

PMID:
30337059
21.

Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer.

Guedes LB, Morais CL, Fedor H, Hicks J, Gurel B, Melamed J, Lee P, Gopalan A, Knudsen BS, True LD, Scher HI, Fine SW, Trock BJ, De Marzo AM, Lotan TL.

Arch Pathol Lab Med. 2019 Mar;143(3):338-348. doi: 10.5858/arpa.2018-0068-OA. Epub 2018 Oct 8.

PMID:
30295067
22.

PTEN status assessment in the Johns Hopkins active surveillance cohort.

Tosoian JJ, Guedes LB, Morais CL, Mamawala M, Ross AE, De Marzo AM, Trock BJ, Han M, Carter HB, Lotan TL.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):176-181. doi: 10.1038/s41391-018-0093-2. Epub 2018 Oct 2.

23.

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.

Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59-65. doi: 10.1038/s41391-018-0086-1. Epub 2018 Aug 31.

24.

Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer.

Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL.

Oral Oncol. 2018 Sep;84:134-136. doi: 10.1016/j.oraloncology.2018.06.026. Epub 2018 Jun 28. No abstract available.

PMID:
30122219
25.

Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.

Trabzonlu L, Kulac I, Zheng Q, Hicks JL, Haffner MC, Nelson WG, Sfanos KS, Ertunc O, Lotan TL, Heaphy CM, Meeker AK, Yegnasubramanian S, De Marzo AM.

Cold Spring Harb Perspect Med. 2019 Apr 1;9(4). pii: a030403. doi: 10.1101/cshperspect.a030403. Review.

PMID:
30082453
26.

Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.

Alharbi AM, De Marzo AM, Hicks JL, Lotan TL, Epstein JI.

Am J Surg Pathol. 2018 Oct;42(10):1286-1296. doi: 10.1097/PAS.0000000000001112.

PMID:
29944471
27.

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer.

Kaur HB, Guedes LB, Lu J, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tosoian JJ, Tomlins SA, Schaeffer EM, Joshu CE, Sfanos KS, Lotan TL.

Mod Pathol. 2018 Oct;31(10):1539-1552. doi: 10.1038/s41379-018-0083-x. Epub 2018 May 30.

28.

ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.

Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL.

Prostate. 2018 Sep;78(12):896-904. doi: 10.1002/pros.23646. Epub 2018 May 15.

29.

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 Aug 15;24(16):3908-3916. doi: 10.1158/1078-0432.CCR-17-2745. Epub 2018 May 14.

30.

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC.

Gigascience. 2018 Jun 1;7(6). doi: 10.1093/gigascience/giy050.

31.

Microsatellite instability in prostate cancer by PCR or next-generation sequencing.

Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC.

J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y.

32.

The Androgen Signaling Axis and Risk Stratification for High-grade Prostate Cancer.

Tosoian JJ, Lotan TL.

Eur Urol. 2018 Aug;74(2):155-156. doi: 10.1016/j.eururo.2018.03.012. Epub 2018 Mar 26. No abstract available.

PMID:
29598983
33.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

34.

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.

Graham L, Banda K, Torres A, Carver BS, Chen Y, Pisano K, Shelkey G, Curley T, Scher HI, Lotan TL, Hsieh AC, Rathkopf DE.

Invest New Drugs. 2018 Jun;36(3):458-467. doi: 10.1007/s10637-018-0578-9. Epub 2018 Mar 6.

35.

Clinical implications of PTEN loss in prostate cancer.

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL.

Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Review.

PMID:
29460925
36.

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.

Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.

Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25.

37.

p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.

Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):260-268. doi: 10.1038/s41391-017-0027-4. Epub 2018 Jan 4.

PMID:
29302046
38.

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.

Tsai HK, Lehrer J, Alshalalfa M, Erho N, Davicioni E, Lotan TL.

BMC Cancer. 2017 Nov 13;17(1):759. doi: 10.1186/s12885-017-3729-z.

39.

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.

Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C, Sauter G, Schlomm T, Simon R.

Oncotarget. 2017 Jul 10;8(39):65566-65576. doi: 10.18632/oncotarget.19217. eCollection 2017 Sep 12.

40.

mTORC1 loss impairs epidermal adhesion via TGF-β/Rho kinase activation.

Asrani K, Sood A, Torres A, Georgess D, Phatak P, Kaur H, Dubin A, Talbot CC Jr, Elhelu L, Ewald AJ, Xiao B, Worley P, Lotan TL.

J Clin Invest. 2017 Nov 1;127(11):4001-4017. doi: 10.1172/JCI92893. Epub 2017 Sep 25.

41.

MSH2 Loss in Primary Prostate Cancer.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL.

Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.

42.

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.

Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, Netto GJ, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S.

Nat Commun. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8.

43.

Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.

Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA.

Eur Urol. 2017 Nov;72(5):845-852. doi: 10.1016/j.eururo.2017.05.009. Epub 2017 May 19.

44.

Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Guedes LB, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto GJ, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL.

Clin Cancer Res. 2017 Aug 15;23(16):4693-4703. doi: 10.1158/1078-0432.CCR-17-0257. Epub 2017 Apr 26.

45.

Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.

Torres A, Alshalalfa M, Tomlins SA, Erho N, Gibb EA, Chelliserry J, Lim L, Lam LLC, Faraj SF, Bezerra SM, Davicioni E, Yousefi K, Ross AE, Netto GJ, Schaeffer EM, Lotan TL.

J Mol Diagn. 2017 May;19(3):475-484. doi: 10.1016/j.jmoldx.2017.01.007. Epub 2017 Mar 21.

46.

Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.

Lotan TL, Torres A, Zhang M, Tosoian JJ, Guedes LB, Fedor H, Hicks J, Ewing CM, Isaacs SD, Johng D, De Marzo AM, Isaacs WB.

Oncotarget. 2017 Apr 4;8(14):22772-22782. doi: 10.18632/oncotarget.15196.

47.

Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy.

Matulewicz RS, Tosoian JJ, Stimson CJ, Ross AE, Chappidi M, Lotan TL, Humphreys E, Partin AW, Schaeffer EM.

J Urol. 2017 May;197(5):1245-1250. doi: 10.1016/j.juro.2016.11.102. Epub 2016 Dec 1.

PMID:
27916711
48.

Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.

Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ, Pomper MG, Lotan TL, Ross AE.

Clin Genitourin Cancer. 2017 Feb;15(1):e65-e68. doi: 10.1016/j.clgc.2016.09.002. Epub 2016 Sep 19. No abstract available.

49.

PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.

Guedes LB, Tosoian JJ, Hicks J, Ross AE, Lotan TL.

J Urol. 2017 Apr;197(4):1054-1059. doi: 10.1016/j.juro.2016.09.084. Epub 2016 Sep 28.

PMID:
27693448
50.

PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Eur Urol Focus. 2016 Jun;2(2):180-188.

Supplemental Content

Loading ...
Support Center